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ObituaryMichael Neuberger (1953–2013)Michael Neuberger captivating Fred Alt with new ideas about somatic hypermutation
mechanisms in a Freiburg, Germany cafe (left). Michael Neuberger and Michael Reth on a
short break from an immunology meeting in Basel, Switzerland (right).The scientific community has been
shocked by the untimely passing of
Michael Neuberger, a brilliant molecular
immunologist who, over the last three de-
cades, has made remarkable scientific
contributions to our understanding of the
molecular mechanisms by which effective
antibodies are generated.
Michael was born in London, UK, as a
member of a tremendously talented and
successful family and was likely influ-
enced in his career path and affinity for
biochemistry by his father, Albert Neu-
berger, who was elected a Fellow of the
Royal Society for his ground-breaking ac-
complishments in biochemistry. Michael
studied at Westminster School from
which he won a scholarship to study Nat-
ural Sciences at Trinity College in Cam-
bridge. He obtained his Ph.D. in biochem-
istry from Imperial College in London,
working under the supervision of Brian
Hartley on the use of bacteriophages to
study gene duplications in bacteria. After
his Ph.D., Michael became interested in
antibodies and wished to continue his
postdoctoral training in Cambridge with
Ce´sar Milstein who, along with Georges
Ko¨hler, was to win the Nobel Prize in
1984 for their work on the development
of monoclonal antibodies. At the recom-
mendation of Milstein in 1979, Michael
first spent a postdoctoral year in Germany
with Klaus Rajewsky at the University of
Cologne, to receive more in-depth immu-
nology training. Michael’s father, Albert,
was a German-born Jewish biochemist
who had to emigrate after the Nazi party
came to power. Michael maintained a
great interest in the post-war develop-
ment of Germany and had strong ties to
its scientific community. The training he
received in Cologne, where he worked
on the variability of antibodies and
their effector functions in activating the
complement system, would serve him
extremely well in his independent career;
and Neuberger and Rajewsky remained
very close both personally and scientifi-
cally over the years.
Following his work with Rajewsky,
Michael joined Milstein in Cambridge
in 1980 to pursue antibody gene regula-
tion and diversification. His early work
focused on the regulation of antibodygene expression, which led him over the
years to identify a surprising multiplicity
of enhancer elements downstream of
the immunoglobulin heavy and light
chain loci; these ‘‘30 enhancers’’ are now
known as major players in the secondary
diversification of antibody genes. As an
outgrowth of this work,Michael pioneered
the use of antibody expression systems in
combination with recombinant DNA tech-
niques to engineer new features into anti-
gen-specific antibodies that allowed him
to elucidate functions for different classes
of B cell antigen receptors. This work
also laid the foundation for the produc-
tion of engineered monoclonal antibodies
suitable for therapy in man, including
chimeric antibodies, complementarity-
determining region (CDR)-grafted anti-
bodies, and human antibodies from trans-
genic mice.
Early on during this phase of his career,
Michael fortuitously was sharing an office
with Greg Winter, who was at that time
pioneering application of oligonucleotide
synthesis and mutagenesis to investigate
enzyme (amino-acyl tRNA synthetase)
catalysis. Michael had been working on
the immunoglobulin heavy (IgH) variable
region of a mouse anti-NP antibody that
was developed in the Rajewsky lab.
The complementary interests sparked a
collaboration between Neuberger and
Winter in which they grafted the anti-NP
mouse IgH variable regions into the
frameworks of a humanmyeloma IgH pro-
tein. Their studies of this recombinantImmunity 39, Dantibody revealed that a human IgGmole-
cule with desired antigen specificity could
be generated by replacing just its CDRs
with those from an antigen-specific
mouse antibody. Winter went on with
others to further develop this CDR-graft-
ing approach and generated the first set
of therapeutic ‘‘humanized’’ antibodies.
Michael then went on to collaborate
with Marianne Bruggemann to show that
transgenic mice bearing human immu-
noglobulin mini-loci could be used for
human monoclonal antibody production.
This strategy was subsequently further
developed by various biotechnology
companies to generate humanized
mouse strains that continue to provide
clinically successful therapeutic human
antibodies.
Among his many scientific contribu-
tions, Neuberger’s more recent discov-
eries on how antibody genes are further
diversified by a DNA deamination mecha-
nism are particularly noteworthy. To those
of us who knew him well, it seems that his
contributions to solving this long-standing
puzzle, which required the full force of his
notable intellectual and technical capabil-
ities, also gave him the most satisfaction.
Tasuku Honjo discovered the Activation-
Induced Cytidine Deaminase (AID)
enzyme and, along with Alain Fischer
and Anne Durandy, he showed that AID
is required for both IgH class-switch
recombination (CSR) to generate different
classes of antibodies and for somatic
hypermutation (SHM) of antibody variableecember 12, 2013 ª2013 Elsevier Inc. 987
Immunity
Obituaryregions, which forms the basis for anti-
body affinity maturation. The puzzle,
though, was how the small AID protein
could initiate DNA strand breaks (DSBs)
required for CSR and mutations required
for SHM. Based on homology of AID to
APOBEC1, an RNA-editing enzyme, one
possibility was that AID might function
by editing RNA to generate novel tran-
scripts that encode mutator or DNA
break-generating enzymes. However,
Neuberger, along with Mathew Scharf
and others, proposed that AID functions
by deaminating deoxycytidine in the
DNA of Ig loci and, thereby, triggers
downstream events that lead to DSBs
for CSR and mutations for SHM, with the
different outcomes resulting from down-
stream pathways used for resolving the
initiating AID-generated lesions.
It is notable that the elaboration of this
pathway and the prediction that AID
would act as a DNA deaminase was built
on a careful dissection of antibody hyper-
mutation mechanisms that was carried
out by Michael Neuberger along with Mil-
stein and Cristina Rada, a close colleague
for decades who codirected Neuberger’s
Cambridge laboratory, as well as by
several others in the field. In this regard,
early models of SHM were based mainly
on some form of error-prone DNA synthe-
sis. But based on their studies of differen-
tial outcomes of SHM in normal germinal
center B cells versus that found in
mismatch repair mutant GC B cells or
in cell culture SHM models, Michael Neu-
berger and his colleagues suggested that
SHM occurs in two phases, with the first
phase focused on C:G pairs and the sec-
ond moving from initiating C:G pairs to
A:T pairs. In addition, effects of mismatch
repair deficiency onCSR ledNeuberger to
also focus on parallels between SHM and
CSR, including the similarity of potential
target DNA hotspots for the two pro-
cesses. This line of thought formed the
basis for Neuberger’s model that AID
could trigger both CSR and SHM by
deamination of cytidines in C:G pairs
to form U:G lesions. He provided proof
of principle for this hypothesis with his
finding that AID could mutate E. coli
through the introduction of nucleotide
transition mutations selectively at C:G
pairs. The DNA cytidine deaminase activ-
ity of AID subsequently was confirmed at
the biochemical level by others. In the988 Immunity 39, December 12, 2013 ª2013meantime, Michael Neuberger went on
to perform a series of beautiful genetic
studies that showed deficiencies for
particular base excision repair factors or
mismatch repair factors perturbed CSR
and SHM exactly as predicted by his
model. Neuberger also added further sup-
port for the model with the demonstration
that altering the AID active site alters the
SHM spectrum.
Michael was not only an outstanding
scientist but also a talented teacher.
Every other year for several decades,
some of us had the privilege of hearing
Michael lecture to a new generation of
young immunologists at the FEBS sum-
mer school for immunology. In his lec-
tures, one not only discovered him to be
an original molecular and biochemical
thinker but also an intellectual with a
broad interest in the history of science
and a profound knowledge of the scienti-
fic literature. Students listening to his lec-
tures learned the newest details of how
somatic mutations are introduced into
antibodies and how these discoveries fit
into the historical context of immunology.
Michael’s scientific colleagues also en-
joyed listening to his lectures and greatly
appreciated his fine sense of humor.
Beyond science, Michael was a kind,
charming, and enthusiastic person with
diverse interests. When we would first
see him at an international meeting or, if
lucky enough, when he hosted us in Cam-
bridge, he invariably greeted us with his
very characteristic warm smile and then
proceeded into an enthusiastic discus-
sion of what had transpired since we
had last met (Figure 1). He was a great
sports enthusiast and quite at home on
any ski slope and willing to take on new
challenges such as spending hours of
ups and downsworking on getting himself
and his colleagues up to speed on a wind-
surfing board. Long walks with Michael,
particularly around and through Cam-
bridge, were a treat, as were dinners and
receptions. These events with Michael
were particularly notable for inspired con-
versations about science, world affairs, or
just about any other topic that came to
mind. Michael was a very critical and
cautious scientist, but his outlook on sci-
ence and people always came from a
positive perspective. He was a creative,
committed, generous, and open man.
He was simply a joy to interact with, andElsevier Inc.there was no better person with whom
to discuss your latest results.
Michael Neuberger’s outstanding sci-
entific contributions have been acknowl-
edged by many prestigious awards,
including the Novartis Medal in 2002 and
the GlaxoSmithKline Prize in 2003. In
1993, he followed his father in becoming
a Fellow of the Royal Society in England,
and in May 2013, he was elected as
a Foreign Associate of the US National
Academy of Sciences. The latter is
perhaps the greatest honor that the
United States can bestow upon a foreign
scientist. It recognizes not only seminal
scientific contributions but also personal
attributes including local leadership and
statesmanship more broadly. In addition
to making so many important contri-
butions to the antibody field, Michael
Neuberger played a leading role at the
MRC laboratory of Molecular Biology in
Cambridge for many years. He was an
outstanding scientist and colleague, a
truly supportive mentor, and a generous
member of the worldwide scientific com-
munity. He will be remembered for his
ability to engage and enlighten people
around him. Michael was blessed with a
loving and supportive family, a large cadre
of scientific colleagues and personal
friends, and a set of devoted and suc-
cessful trainees who all will miss him
very much.
When told of Michael Neuberger’s
passing, our colleague David Balti-
more nicely captured our own thoughts:
‘‘Michael was a prince among men. Crea-
tive, committed, urbane, understated,
and even loveable. What a great loss!’’
We can only take solace in our wonderful
memories ofMichael Neuberger and in his
many lasting contributions to our field.Frederick Alt1,*
and Michael Reth2,*
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